PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer

Author:

Taylor Amelia M1,Chan David Lok Hang12,Tio Martin1,Patil Sujata M3,Traina Tiffany A4,Robson Mark E4,Khasraw Mustafa5

Affiliation:

1. Medical Oncology; Royal North Shore Hospital; Sydney Australia

2. Faculty of Medicine and Health, Northern Clinical School; University of Sydney; Sydney Australia

3. Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY USA

4. Department of Medicine; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College; New York NY USA

5. NHMRC Clinical Trials Centre, The University of Sydney; Camperdown Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference80 articles.

1. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study);Balmana;Cancer Research,2016

2. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer;Diéras;Cancer Research,2017

3. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study;Han;Annals of Oncology,2018

4. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study;Han;Cancer Research,2017

5. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale;Isakoff;Future Oncology,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3